Evolving therapies: farnesyltransferase inhibitors.

被引：28

作者：

Purcell W.T. ^{[1
]}

Donehower R.C. ^{[1
]}

机构：

[1] The Johns Hopkins Oncology Center, Bunting-Blaustein Cancer Research Building, Room, 1650 Orleans Street, Baltimore, 21231-2410, MD

来源：

Current Oncology Reports | 2002年 / 4卷 / 1期

关键词：

Topotecan; Farnesyl; Advanced Solid Tumor; Proc ASCO; Evolve Therapy;

D O I：

10.1007/s11912-002-0045-8

中图分类号：

学科分类号：

摘要：

Farnesyltransferase inhibitors (FTIs) are compounds designed to interfere with the signal transduction of cancer cells containing ras gene mutations. Specifically, FTIs were designed to prevent the farnesylation of Ras and other intracellular proteins, and they have been shown to have an effect on malignant cell proliferation and survival. However, the actual intracellular target of FTIs and the cellular determinants of drug action that correlate with antitumor effects currently are unknown. The following are key questions relating to FTI cell biology and clinical development: 1) Are ras gene mutations required for FTIs to be effective? 2) Does the effect of FTI therapy depend on which ras isoform is active (ie, H-ras, K-ras4A/B, or N-ras) in cancer cells? 3) What level of farnesyltransferase inhibition is required for clinical effect? 4) What surrogate biomarkers can be used to evaluate the biologic effect of FTIs in ongoing clinical trials? 5) What is the mechanism of FTI antitumor activity? Although the preliminary results are encouraging, more understanding of the intracellular mechanism of the FTIs is needed to determine how best to administer them in patients with cancer and to test their antitumor effects.

引用

页码：29 / 36

页数：7

共 179 条

[1]

Gibbs JB(1994)Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic Cell 77 175-178

[2]

Oliff A(2001)Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 93 1062-1074

[3]

Kohl NE(2000)The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo Cancer Chemother Pharmacol 46 387-393

[4]

Adjei AA(2000)Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies Oncogene 19 6584-6593

[5]

Shi B(2000)Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects Curr Opin Cell Biol 12 166-173

[6]

Yaremko B(2001)Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood 97 3361-3369

[7]

Hajian G(1999)Targeting farnesyltransferase: is Ras relevant? Drug Resist Updat 2 81-84

[8]

Sebti SM(2001)The farnesyl transferase inhibitor SCH 66336 induces a G(2) to M or G(1) pause in sensitive human tumor cell lines Exp Cell Res 262 17-27

[9]

Hamilton AD(1999)Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development J Clin Oncol 17 3631-3652

[10]

Prendergast GC(2000)Ras-induced cellular events [review] Mol Membr Biol 17 65-73

← 1 2 3 4 5 6 7 8 9 10 →